Company / R&D Expense
Solid Biosciences Inc. R&D Expense History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$64.9M
FY2022
5-year range
$20.1M / $94.7M
FY2018-FY2022
Trend
-31.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $58M to $65M over the past 2 years.
Based on SEC 10-K filings.
$65M in FY2022 with a 3-year CAGR of +17.6%.
Improved from $58M to $65M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +17.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +17.6%, indicating consistent growth.
- In FY2022, r&d expense decreased 31.5% year-over-year.
- Peak r&d expense was recorded in FY2021.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $64.9M | -31.5% |
| FY2021 | $94.7M | +63.4% |
| FY2020 | $58.0M | +45.3% |
| FY2019 | $39.9M | +98.4% |
| FY2018 | $20.1M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026